Generare Bioscience SAS, a Paris-based biotechnology company generating never-before-seen molecular data for drug development using artificial intelligence, announced today it has raised €20 million, about $23.3 million, in an early-stage funding round co-led by Alven and Daphni.

All existing investors, including Galion.exe, Teampact Ventures and Vives Partners, joined the Series A round.

Founded in 2023, Generare is building the largest dataset of undiscovered molecular chemistry and categorizing it within a library of compounds characterized by structure, biological activity and drug potential. 

The company said much of the pharmaceutical industry has operated within a very narrow chemical window for decades — not by choice, but because the data didn’t exist. Generare unlocks information encoded within microbial genomes, where a vast trove of molecular information has been stored and evolution spent 3 billion years working.

Generare estimates that about 97% of the genomic data available to humanity remains buried in microbial genomes, unread. Generare said it’s generating value from this missing data, providing it at quality and scale.

Microbial genomes have been a rich source for drug discovery. Examples of drugs that have been derived from microbes include Lugdunin, an antibiotic taken from a bacterium found in the human nose; Taromycin A/B, discovered in the Actinobacteria genome, an antibiotic capable of fighting Methicillin-resistant Staphylococcus aureus, a devastating antibiotic-resistant infection; and Vidarabine, an antiviral drug derived from a marine sponge-associated fungus.

The company specializes in small molecules – a class of chemistry that the best-known medicine is built on.

”Drug discovery has a data problem. The entire field trains its models on the same recycled chemistry and expects different outcomes,” co-founder and Chief Executive Guillaume Vandenesch said. “The bottleneck is not algorithms, it is the absence of genuinely novel, high-quality molecular data and we’re solving that by building the largest proprietary dataset of cryptic small molecules.”

By providing a tranche of novel, newly discovered small molecule data found within undiscovered microbial genomic territory, Generare expects to revolutionize the current AI drug discovery industry. In 2025 alone, all other players combined discovered a few dozen new molecules; Generare discovered more than 200.

The company said it will use the funding to greatly accelerate that pattern of discovery by scaling its capacity 10-fold by 2027 to more than 2,000 molecules, with an aim to exceed 10,000 over time. It also intends to double its team of 25 computational biologists, chemists, synthetic biologists, technicians and engineers.

Photo: Generare Bioscience